At a glance
- Originator Merck & Co
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action AMPA receptor antagonists; Glycine NMDA-associated antagonists; NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 07 Jan 2000 Discontinued-Preclinical for Epilepsy in USA (Unknown route)